The pRb tumour suppressor protein has a central role in coordinating early cell cycle progression. An important level of control imposed on pRb occurs through posttranslational modification, for example, phosphorylation. We describe here a new level of regulation on pRb, mediated through the targeted methylation of lysine residues, by the methyltransferase Set7/9. Set7/9 methylates the C-terminal region of pRb, both in vitro and in cells, and methylated pRb interacts with heterochromatin protein HP1. pRb methylation is required for pRbdependent cell cycle arrest and transcriptional repression, as well as pRb-dependent differentiation. Our results indicate that methylation can influence the properties of pRb, and raise the interesting possibility that methylation modulates pRb tumour suppressor activity.
Introduction
The retinoblastoma tumour suppressor protein (pRb) functions in early cell cycle control by negatively regulating entry into S-phase (Weinberg, 1995) . A key target in this process involves the E2F family of transcription factors, with which pRb interacts and thereby controls their transcriptional activity (Stevens and La Thangue, 2003) . Consequently, genes required for entry into S-phase are no longer expressed and cells fail to undergo cell cycle progression. In addition to cell cycle control, pRb activity is intimately connected with other types of cell fate,, including differentiation, senescence and apoptosis (Classon and Harlow, 2002; Giacinti and Giordano, 2006) . For example, Rb À/À mice exhibit embryonic lethality resulting from cell autonomous and non-cell autonomous effects, causing a lack of cellular differentiation and increased levels of apoptosis in diverse tissues (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992; van den Heuvel and Dyson, 2008) . in vitro, pRb drives differentiation in different lineages, including osteoblasts and myoblasts, which involves pRb-dependent repression and cell cycle exit, together with transcriptional activation of differentiation-inducing transcription factors, such as MyoD and CBFA1 (Gu et al., 1993; Thorburn et al., 1993; Lipinski and Jacks, 1999; Novitch et al., 1999; Thomas et al., 2001; Huh et al., 2004) .
The tumour suppressor activity of pRb is regulated in part through post-translational modification, principally phosphorylation, directed by cyclin-dependent kinase Cdk (Classon and Harlow, 2002; Giacinti and Giordano, 2006) . Serial phosphorylation events mediated by cyclin/Cdk complexes that occur during cell cycle progression inactivate pRb tumour suppressor activity, resulting in the release of E2F and cell cycle progression (Sherr, 2000) . Although phosphorylation is established as an important mechanism in pRb control, other levels of post-translational regulation affect pRb activity. Acetylation in the C-terminal region of pRb occurs within a docking site for cyclinE/Cdk2, preventing cyclin/Cdk binding that subsequently diminishes the level of pRb phosphorylation (Chan et al., 2001; Nguyen et al., 2004) . The same residues undergo acetylation during DNA damage, suggesting that pRb acetylation is integrated with checkpoint control (Markham et al., 2006) .
Lysine residues undergo different types of posttranslational modifications (Zhang and Reinberg, 2001 ). In the tail region of core histones, lysine residues are targeted by acetylation, methylation, phosphorylation and ubiquitin-like modifications. The nature of the modification frequently has functional consequences on chromatin and transcription, and has led to the concept of the histone code (Jenuwein and Allis, 2001 ). Lysine methylation takes on an integral role in orchestrating chromatin control, resulting in either an increase or decrease in activity, reflecting the particular histone residue targeted and the type of methylation event that occurs (Kouzarides, 2007) . Frequently, methylated lysine residues bind heterochromatin protein (HP1) proteins, which are often associated with long-term gene silencing and transcriptional inactivity, through the formation of dense chromatin structures (Hediger and Gasser, 2006) . A family of lysine methyltransferases has been described, typically characterized by a conserved Set domain (Zhang and Reinberg, 2001; Xiao et al., 2003) . In addition to histones, the mono-methyltrans-ferase Set7/9 has been shown to methylate lysine residues in non-histone proteins, including proteins involved with transcriptional control TAF10, p53 and the oestrogen receptor (Chuikov et al., 2004; Kouskouti et al., 2004; Subramanian et al., 2008) .
We reasoned that lysine residues in pRb may be targets for different types of post-translational control. To this end, we report here that pRb undergoes lysine methylation, both in vitro and in cells, and show that one of the methyltransferases responsible is the monomethyltransferase Set7/9. Methylation prompts the interaction between pRb and HP1, and methylation is required for efficient pRb-dependent transcriptional repression, cell cycle exit, senescence and differentiation.
Our results establish that methylation influences the activity of pRb, and thereby define methyltransferase as a new group of enzymes involved with pRb and cell cycle control.
Results

pRb is methylated
We expressed and purified methyltransferases in recombinant form and assessed their ability to methylate pRb in vitro. One of the enzymes tested, the monomethyltransferase Set7/9 (Xiao et al., 2003) , could methylate pRb (Figures 1b, c and d) . Other mono- Figure 1 Retinoblastoma protein (pRb) is methylated by Set7/9. (a) Schematic diagram of pRb: the N-and C-terminal regions are bracketed with the A and B pocket domains indicated. The numbers indicate the amino-acid residue position of the boundaries of the respective domains. The region 870-876 is expanded with the site of methylation identified in the current study indicated (K873). (b) Filter-based methylation assay by Set7/9: about 1 mg of the indicated substrate glutathione-S-transferase (GST)-Rb proteins were methylated by Set7/9 (1 mg) in the presence of 3 H SAM. Rb RR had residue substitutions at K873 and K874, and K873A, a single substitution at K873. (c) Filter-based methylation assay by Set8: about 1 mg of GST-pRb was treated with Set8 or Set7/9 (1 mg) in the presence of 3 H SAM. Autoradiograph of SDS-PAGE methylation assay: Set7/9 (1 mg) with core histones (His; lane 1;1 mg), GST (lane 2;1 mg) or GST-Rb (lane 3;1 mg), respectively. The position of methylated GST-Rb is indicated; methylated histones and Set7/9 are also indicated. The protein-stained gel is shown in Supplementary Figure 1j . (e) An SDS-PAGE Coomassie blue-stained gel showing purified GST-Set7/9 and GST-pRb (about 1 mg) used in the in vitro methylation assays (b, c, d and f). (f) GST-pRb was methylated by Set7/9 as described and immunoblotted (IB) with anti-Me873 antibody in the presence of methylated (Me) or unmethylated peptide (WT; 5 mg/ml). Note that each lane was derived from the same blot and was sliced to allow separate treatments with the indicated antibody/peptide mix. (g) Endogenous pRb methylation: U2OS cell extracts were immunoprecipitated with anti-pRb (lanes 1-3) or a non-specific (NS) antibody (lanes 4 and 5) and the immunoprecipitates immunoblotted with either anti-pRb (lane 1) or anti-MeK873 antibody (lanes 2, 3, 4 and 5) in the presence of methylated (Me; lanes 2 and 4) or unmethylated (WT; lanes 3 and 5) K873 peptide (5 mg/ml). Note that all lanes were derived from the same immunoblot, and that each lane was cut in half to allow a direct comparison after treatment with the indicated antibody-peptide mix. methyltransferases, such as Set8, failed to methylate pRb, in contrast to the methylation of histones ( Figure 1c and Supplementary Figure 1i) .
To establish the role of pRb methylation, we sought to identify lysine residues that are modified by methylation. Different regions of pRb were tested as substrates for in vitro methylation, which mapped Set7/9 methylation to the C-terminal region containing K873/874 (data not shown). As a consequence, we examined whether residues K873/874 were modified by Set7/9. In contrast to wild-type pRb, a mutant pRb derivative, in which both K873 and K874 had been altered to RR, was poorly methylated (Figures 1a and b) . Further, as a mutant pRb derivative with a single residue substitution, K873A, could not be efficiently methylated (Figure 1b Figure 1a ), K873 is likely to be a site of methylation.
To verify K873 as a Set7/9 methylation site, we prepared a modification-specific antibody directed against a pRb peptide in which K873 had been monomethylated. The anti-Me-K873 peptide antibody efficiently recognized the mono-methylated peptide and exhibited negligible activity against the unmethylated peptide ( Supplementary Figures 1a and b) . Furthermore, when the anti-Me-K873 antibody was assessed by immunoblotting against glutathione-S-transferase (GST-Rb), the antibody bound very effectively after in vitro methylation of GST-Rb by Set7/9 (Figures 1e and f, lanes 2 and 4).
To address the specificity of the anti-Me-K873 peptide antibody for Set7/9 methylated pRb, the ability of matched peptides that differ only by a single methyl group on residue K873 to compete for antibody binding was studied. At equivalent concentration, the monomethylated peptide (Me) competed with anti-Me-K873 binding to in vitro methylated pRb in contrast with the unmethylated peptide (WT), that competed less efficiently (Figure 1f , lanes 3 and 4). Whether pRb is methylated in cells was assessed using the anti-Me-K873 antibody to study pRb methylation in U2OS cells. By immunoprecipitating endogenous pRb followed by immunoblotting, the methylation of endogenous pRb in U2OS cells was detected (Figure 1g ). Moreover, anti-Me-K873 binding was efficiently competed for by the mono-methylated peptide and much less by the unmodified peptide (Figure 1g ), suggesting that endogenous pRb is methylated at K873. The reduced methylation of K873A (Figure 1b) , and the binding properties of anti-Me-K873 antibody to Set7/9-methylated pRb (Figure 1f ) and pRb in cells (Figure 1g ) strongly suggest that K873 is a residue that can be mono-methylated. However, these results do not exclude other sites of methylation in pRb.
The role of endogenous Set7/9 in mediating pRb methylation was studied through small interfering RNA (siRNA)-dependent depletion. For this, we identified a siRNA that depleted endogenous Set7/9 in U2OS cells (Supplementary Figure 1c and d) , and then assessed the effect of Set7/9 siRNA on K873 methylation. The introduction of Set7/9 siRNA resulted in reduced binding of anti-Me-K873 to ectopic pRb immunoprecipated from U2OS cells (Supplementary Figure 1e) . Conversely, expression of ectopic Set7/9 resulted in increased binding of anti-Me-K873 to pRb (Supplementary Figure 1f ). Thus, K873 is methylated in cells, and Set7/9 is an enzyme responsible for the methylation event.
Functional consequences of pRb methylation
We examined the role of methylation on pRb activity by comparing wild-type pRb with K873A in different assay systems. We began by investigating whether the regulation of E2F activity was affected by mutating K873. The effect of wild-type pRb and K873A on E2F site-dependent transcription was measured on the Cdc6 and DHFR promoters, which represent physiological E2F target genes (Stevens and La Thangue, 2003; Frolov and Dyson, 2004 ). Although K873A reduced the level of E2F site-dependent transcription, its ability to repress either promoter was considerably less than that observed for wild-type pRb (Figures 2a and b) . As previously documented (Zamanian and La Thangue, 1992) , the naturally occurring pRb mutant, D22, exhibited minimal repression activity (Figures 2a and b) .
Transcriptional repression by pRb can be measured in the context of a Gal4-pRb hybrid protein on a Gal4-responsive reporter (Weintraub et al., 1992) . When wild-type pRb or K873A was expressed as a Gal4 hybrid, the ability of Gal4-K873A to repress transcription of pSVGa14-tk-luciferase was much less efficient than that of Gal4-pRb ( Figure 2c ). Moreover, the ability of wild-type pRb to repress E2F site-dependent transcription was reduced on Set7/9 depletion, in contrast to the effect of Set7/9 depletion on K873A activity in which minimal effect of Set7/9 siRNA was observed ( Figure 2d and Supplementary Figure 1h) . These results suggest, therefore, that the methylation of K873 facilitates pRb-dependent transcriptional repression.
We examined the effect of Set7/9 depletion on the expression of E2F target genes. In U2OS (pRb þ / þ ) cells, Set7/9 depletion resulted in increased expression of a variety of E2F target genes, including E2F-1, Cdc6, DHFR, Cdc25A and Cdc2 (Figure 2e ). This contrasted with the effect of Set7/9 siRNA in SAOS2 cells, which express a mutated and inactive form of pRb (Shew et al., 1990) , in which Set7/9 depletion failed to alter the level of expression of E2F target genes ( Figure 2f ). These results are consistent with the effect of Set7/9 on E2F target genes mediated through pRb.
pRb methylation and cell cycle control The ability of pRb to suppress proliferation coincides with pRb-dependent regulation of E2F activity (Frolov and Dyson, 2004) . We therefore assessed the growthregulating properties of K873A in SAOS2 cells, under conditions in which ectopic wild-type pRb caused cell cycle arrest. Typically, wild-type pRb caused an increase in the G1 population (usually between 15 and 20% compared with vector alone treatment; Figure 3a and Supplementary Figure 1j ). In contrast, K873A resulted in a smaller increase in the G1 population relative to wild-type pRb (usually 30-50% less than wild-type pRb; Figure 3a ). Both wild-type pRb and K873A underwent comparable nuclear accumulation (Figure 3b ).
Another property of pRb that relates to its tumour suppressor activity is the ability to induce cellular senescence (Templeton et al., 1991) . When introduced into SAOS2 cells, pRb can, under appropriate culture conditions, give rise to a characteristic flat cell morphology that exhibits some similarities with the properties of senescing cells (Templeton et al., 1991) . Typical senescent cells, with the characteristic flat cell morphology and expressing the late senescence marker b-galactosidase (Templeton et al., 1991; Sellers et al., 1998) , were evident for both wild-type pRb and K873A. However, K873A was less efficient at inducing senescent cells compared with wild-type pRb (Figures 3c and d) . Together, these results point to a role for methylation at K873 in the growth-regulating effects of pRb. pRb methylation and HP1 binding As methylated lysine residues in histone tails can bind HP1 (Zhang and Reinberg, 2001) , it was of interest to test whether K873 provided a binding site for HP1. When purified recombinant proteins were assessed for and DHFR-luciferase (b) reporter constructs. U2OS cells transfected with vectors encoding wild-type pRb, K873A or D22 together with E2F-1 and pCMV-bgal as the internal control. Lower panel shows the levels of pRb and E2F-1 detected by immunoblotting. The relative activity (luciferase/b-galactosidase) is indicated, *Po0.007, n ¼ 3, Student's t-test. (c) U2OS cells transfected with vectors encoding Gal4-pRb, Gal4-K873A, Ga14-D22 or Ga14 alone together with pCMV-bgal, and the ability of the fusion proteins to affect pSVGal4-tk-luc luciferase reporter activity measured. The relative activity (luciferase/b-galactosidase) is indicated, **Po0.0001, n ¼ 6, Student's t-test. (d) U2OS cells were treated with either control (C) or Set7/9 (S) small interfering RNA (siRNA). After 24 h, cells were transfected with expression vectors encoding wild-type pRb or K873A together with E2F-1 and pCMV-bgal as the internal control, and the effect on DHFR-luciferase activity was measured. Lower panel shows the level of Set7/9 protein. The relative activity (luciferase/b-galactosidase) is indicated. (e, f) U2OS (e) or SAOS2 (f) cells were treated with either control (C) or Set7/9 (S) siRNA. After 72 h, cells were collected, and the protein expression level of E2F target genes was assessed by immunoblotting. Actin serves as the internal control.
binding, a specific interaction was evident between GSTpRb and HP1, which was enhanced when GST-pRb had been methylated in vitro by Set7/9 (Figure 4a ). By immunoprecipitation, a specific interaction was evident in cells between ectopic pRb and HP1 (Figure 4b) . Each of the different isoforms of HP1 (a, b and g) could bind to pRb, although the interaction was most efficient between pRb and HP1a (Figure 4b) . By assessing the role of endogenous Set7/9 in regulating the pRb-HP1 interaction, the effect of depleting Set7/9 using siRNA was assessed. In conditions of depleted Set7/9, the binding of pRb to HP1 was reduced (Figure 4c ). It is consistent with these results that the interaction between K873A and HP1 was compromised compared with the interaction between wild-type pRb and HP1 (Figures 4b and c) .
We confirmed that the interaction was relevant under physiological conditions by studying the interaction between pRb and HP1 in U2OS cells, in which pRb is methylated (Figure 1g ). pRb was detected in HP1 immunoprecipitates (Figure 4d ), indicating that pRb and HP1 interact. Moreover, the level of pRb in HP1 immunoprecipitates was lower in Set7/9 siRNAtreated cells (Figure 4d) . Similar results on the interaction between pRb and HP1 were observed in MCF7 cells in which Set7/9 depletion compromised the endogenous interaction between pRb and HP1 (Supplementary Figure 1g) . These results suggest that HP1 interacts with pRb, and further that the interaction is dependent on Set7/9 activity and the integrity of K873. To assess the role of HP1 in pRb-dependent cell cycle arrest, we coexpressed pRb or K873A with HP1 in SAOS2 cells. There was a significant increase in the level of G1 arrest when wild-type pRb was coexpressed with HP1, in contrast to the effect of HP1 on K873A in which an increase in G1 population was not apparent (Figure 4e ), suggesting that the interaction between pRb and HP1 is functionally important in mediating cell cycle arrest. Furthermore, when the presence of pRb and HP1 was studied on E2F target genes by chromatin immunoprecipitation, there was an increase in the level of both pRb and HP1 in conditions of growth arrest (Figure 4f ). The ability of pRb and HP1 to locate E2F target genes required Set7/9, because depletion of Set7/9 by siRNA resulted in reduced levels of chromatinassociated pRb and HP1 (Figure 4f) . Together, these results suggest that pRb and HP1 interact in a manner that is dependent on Set7/9 activity, and further that HP1 contributes to the activity of pRb.
pRb methylation and differentiation
The requirement for pRb activity during differentiation has been well documented in myogenesis, in which pRb is necessary for myoblasts to reach a terminally differentiated state (Zacksenhaus et al., 1996) . We therefore investigated the role of pRb and its methylation in two myoblast cell lines: C2C12, which expresses endogenous wild-type pRb, and CC42 (Rb À/À ), which undergoes differentiation on expressing ectopic pRb (Wang et al., 1997) .
As expected, an increase in myosin heavy chain (MHC) expression, which is differentiation-dependent, occurred on differentiation of C2C12 cells, in contrast to pRb levels, which remained at a similar level (Figure 5a ). When anti-Me-K873 was used to study endogenous pRb methylation, methylated pRb was evident in differentiated cells (Figure 5a) , which, by using the monomethylated and unmodified peptides to compete with anti-Me-K873 binding, was shown to be specific for K873 (Figure 5a ).
To test whether pRb is involved with the requirement for Set7/9 during myoblast differentiation, the effect of Set7/9 depletion in CC42 (Rb À/À ) cells was studied. The CC42 cells differentiate on ectopic pRb expression into multi-nucleate myotube-like cells, which coincides with increased expression of MHC (Figure 5b ; Wang et al., 1997) . Under these conditions, Set7/9 was depleted with siRNA and, thereafter, the level of MHC was measured. The depletion of Set7/9 resulted in reduced MHC expression compared with control treatment (Figure 5b) .
To correlate the effect of Set7/9 with pRb K873, the differentiation-inducing capacity of wild-type pRb to K873A in CC42 cells was compared. Although ectopic wild-type pRb facilitated MHC expression in differentiating medium conditions, the ability of K873A to induce MHC expression in the same conditions was compromised (Figures 5c and d) . There was no apparent effect of pRb on MHC expression in growth medium conditions, in which differentiation did not occur (Figure 5c ). These observations suggest that the Set7/ 9-dependent methylation augments pRb-dependent differentiation.
To establish whether there was an increase in the presence of pRb and HP1 at E2F target genes under conditions of differentiation, chromatin immunoprecipitation on chromatin extracted from asynchronously proliferating and differentiated C2C12 cells was performed. The level of pRb and HP1 on the DHFR E2F site was higher in chromatin prepared from differentiated cells compared with asynchronous proliferating cells (Figure 5e ). Thus, under differentiation conditions in which pRb methylation occurred, an increased presence was apparent for HP1 at E2F target genes.
Discussion
The role of pRb methylation Our studies show that pRb undergoes lysine methylation, and identify Set7/9 as a candidate methyltransferase involved in this process. Specifically, Set7/9 methylated K873 in vitro and in cells. The growthregulating properties of pRb, which were affected by methylation, include cell cycle arrest, senescence and differentiation. Importantly, the repression activity of pRb was compromised in a mutant derivative that lacked the K873 methylation site. (ChIP) analysis of the effect of Set7/9 depletion on pRb and HP1 binding to TS promoter in growth-arrested and proliferating cells. U2OS cells were treated with either control (C) or Set7/9 (S) siRNA, and 24 h later cells were either grown in proliferating conditions (GM) or serum starvation conditions (SS) for 48 h. Cells were treated as described with anti-Rb, anti-HP1a or non-specific mouse IgG antibodies. Note that each data point was derived from triplicate readings, and represents mean plus s.e.
One of the properties of pRb that influences differentiation relates to the need to exit the cell cycle before differentiation can occur, and the incompatibility between proliferation and differentiation (Chen and Wang, 2000; Classon and Harlow, 2002; Huh et al., 2004; van den Heuvel and Dyson, 2008) . Thus, derivatives of pRb that exhibit compromised cell cycle arrest activity, similar to K873A, might be expected to possess defective differentiation-inducing activity, reflecting incomplete cell cycle exit rather than a deficit in a differentiation activity per se. Consequently, results described here suggest a role for lysine methylation in the control of pRb-dependent growth control, and implicate HP1 binding to pRb as an interaction that influences pRb activity, but do not exclude a role for pRb methylation in differentiation (Figure 5f ). 2) . Extracts were immunoprecipitated with anti-pRb (lanes 4 and 5), or a non-specific (NS) antibody (lane 3) followed by immunoblotting with either anti-pRb (lanes 3, 4 and 5) or anti-MeK873 (lanes 6, 7, 8 and 9) in the presence or absence of either the methylated (Me) or unmethylated (WT) peptide (5 mg/ml) as indicated. (b) CC42 cells were treated with either Set7/9 (S) or control (C) small interfering RNA (siRNA; 25 nM) for 24 h and then transfected with expression vectors encoding wild-type pRb or empty control (À) vector for a further 24 h. Cells were washed and replaced with differentiation medium (DM) containing 0.1% fetal bovine serum. After 48 h, extracts were prepared and immunoblotted for MHC, hemagglutinin (HA) (pRb), Set7/9 and lamin (loading control) as indicated. (c) CC42 cells were transfected with expression vectors encoding wild-type pRb, K873A or empty vector (2 mg) as indicated, together with pCMV-b-gal (500 ng) as an internal control. At 24 h post-transfection, cells were treated with differentiation medium (DM) or growth medium (GM; 10% serum) for a further 48 h. Cell extracts were prepared, normalized according to b-galactosidase activity and immunoblotted with anti-MHC and anti-HA. (d) Graphical representation of average MHC expression after 48 h differentiation, relative to pRb levels, and MHC levels depicted are presented relative to the levels of HA-Rb for the results presented in (c). (e) Chromatin immunoprecipitation (ChIP) analysis of pRb and heterochromatin protein 1 (HP1) binding to the DHFR promoter E2F binding site. C2C12 cells were either grown in proliferating (grey) or differentiation (black) conditions for four days. Chromatin was then immunoprecipitated with anti-Rb, anti-HP1a or non-specific (NS) mouse IgG antibodies, and the amount of DHFR promoter in the inputs and immunoprecipitates was measured by quantitative PCR. The data represent mean and s.e., and were derived from triplicate readings. (f) Model depicting the role of pRb methylation and HP1 binding. It is envisaged that HP1 binding allows pRb to repress target genes, which might occur in conditions of permanent cell cycle exit, such as cell cycle arrest, differentiation and senescence.
pRb methylation and methyltransferase Studies on the modifications that take place within the N-terminal tail region of core histones have led to the concept of the histone code, which suggests that the constellation of post-translational modifications that occur in chromatin contribute to the functional activity of the genome (Jenuwein and Allis, 2001 ). Acetylation, methylation and phosphorylation provide major types of modification in the histone code (Kouzarides, 2007) . A further level of complexity occurs with lysine residues, which can be methylated or acetylated, and methylation exists as mono-, di-or tri-methylation, in which the type of methylation event has been linked to the functional consequence on gene activity (Kouzarides, 2007) . For example, tri-methylation of K4 in histone H3 correlates with transcriptional activity (Santos-Rosa et al., 2002) .
Histone methyltransferase has been suggested to have a role in pRb-mediated transcriptional repression (Frolov and Dyson, 2004; van den Heuvel and Dyson, 2008) . Specifically, Suv39H1 physically interacts with pRb, allowing methylation of K9 residue in histone H3 and subsequent binding of the HP1 protein to the methylated lysine side chain (Nielsen et al., 2001) . As a result, histone methylation by Suv39H1 has been connected with the transcriptional repression of E2F target genes, such as cyclin E, and cell cycle arrest. Our results define a further level of complexity in the control of pRb by establishing the direct methylation of pRb. In contrast to the interaction between pRb and Suv39H1, in which core histones are believed to be a primary target for the methylation event (Nielson et al., 2001) , pRb control by Set7/9 is distinct and involves the direct methylation of pRb. Specifically, the interplay between Set7/9 and pRb reflects an enzyme-substrate relationship, in which pRb itself is the target protein for the Set7/9 enzyme. In a similar manner, Set7/9 methylates the p53 tumour suppressor protein (Chuikov et al., 2004; Kurash et al., 2008) , suggesting that Set7/9 integrates different tumour suppressor pathways. Significantly, the methylation of K873 facilitated binding of HP1 to pRb. As HP1 proteins are generally connected with gene silencing and localized to areas of heterochromatin (Fischle et al., 2003; Hediger and Gasser, 2006) , the interaction between pRb and HP1 might be involved with a similar mechanism.
The identification of K873 as a target for monomethylation exhibits a number of parallels with the histone code. For example, the same pRb region is targeted by acetyltransferases, such as p300 (Chan et al., 2001) , and thus, similar to certain lysine residues in histone tails, might be influenced by different types of modification. Perhaps, the methylation of pRb provides a stable type of modification that endows pRb with properties important to exert long-term effects during differentiation (Hediger and Gasser, 2006) , contrasting with acetylation that might provide a more transient type of modification of relevance, for example, during the DNA damage response (Markham et al, 2006) . In this light, pRb methylation by Set7/9 may modify pRb in a manner to prevent re-entry into the cell cycle, thereby facilitating cellular differentiation.
Materials and methods
Plasmids and expression vectors pCdc6-luc, p73-luciferase, DHFR-luc (Fry et al., 1997), pGEXRb (379-928) (Bandara et al., 1991) , pcDNA-HA-Rb (1-928) and pcDNA D22 (Chan et al., 2001) have been previously described. pGEX-Rb-K873R/K874R has been described elsewhere (Markham et al., 2006) . pGEX-Set7/9 has been previously described (Wilson et al., 2002) and pcDNA-Set7/9 was subcloned from pGEX-Set7/9. pGEX-Rb-K873A and pSG5L-HA-Rb-K873A were generated by site-directed mutagenesis from pGEX-Rb and pSG5L-HA-Rb using a Quickchange Site-Directed Mutagenesis kit (Stratagene, Amsterdam, The Netherlands). For pcDNA Myc/His HP1a, b and g, and pET28aHP1a, HP1a, b and g were PCR subcloned into pcDNA3.1myc/his mammalian expression vector or pET28a bacterial expression vector from IMAGE clones 3448801, 3140815 and 3450099, respectively (Geneservice, Cambridge, UK).
Anti-Me-K873 peptide antibody
The rabbit polyclonal anti-Me-K873 antibody was generated and purified by Eurogentec (Southampton, UK). Briefly, a synthetic pRb peptide was generated containing residues 863-877 (C-AEGSNPPKPLKKLRF-C), in which lysine 873 (bold) was made with mono-methyl lysine. This peptide was used to immunize rabbits. The resulting polyclonal antibody was purified by passing the crude antiserum through a methyl K873 pRb peptide column, and the bound material was then passed through a second column containing the nonmethylated peptide.
Tissue culture and transfection CC42(Rb À/À ) cells were as described previously (Wang et al., 1997) . CC42, C2C12, U2OS and SAOS2 cells were cultured in Dulbecco modified Eagle medium (DMEM) (Invitrogen, Paisley, UK) supplemented with 10% fetal calf serum (FCS) and penicillin-streptomycin (Invitrogen) at 37 1C in 5% CO 2 . CC42 cells were transfected with Effectene (Qiagen, Crawley, UK) or Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Other cell lines were transfected with GeneJuice (Novagen, Nottingham, UK). C2C12 and CC42 cells were differentiated by replacing the growth media with 0.1% serum in DMEM for 48 h (differentiating medium). Subsequently, serum was reintroduced for 16 h with 10% serum in DMEM. The growth medium contained 10% serum.
Immunoprecipitation and immunoblotting
Cells were collected, washed in phosphate buffered saline (PBS) and resuspended in TNN buffer (50 mM Tris (pH 7.4), 5 mM EDTA, 0.5% Igepal CA-630 (Sigma, Poole, UK), 50 mM NaF, 1 mM DTT, 0.2 mM Na 3 VO 4 , 120 mM NaCl, protease inhibitor cocktail (Roche, Welwyn Garden City, UK)). Total protein concentration was determined by Bradford Assay (Bio-Rad, Hemel Hempstead, UK). Typically, 1-1.5 mg of cell extract was added to pre-washed Protein-G agarose beads (Sigma) with 1 mg of antibody. After overnight incubation, beads were washed four times in TNN before protein elution with 2 Â SDS loading buffer and analysed by SDS-PAGE and immunoblotting with the appropriate antibodies. The following antibodies were used for immunoblotting; anti-HA.11 monoclonal (Covance, Denver, PA, USA), anti-pRb monoclonal 4H1 (Cell Signaling Technology, Beverly, MA, USA), anti-pRb polyclonal C-15 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-GST monoclonal (Santa Cruz Biotechnology), anti-myc monoclonal 9E10 (Santa Cruz Biotechno-logy), anti-PCNA monoclonal PC10 (Santa Cruz Biotechnology), anti-HP1a (Millipore, Dundee, UK), anti-MHC monoclonal A4.1025 (Millipore), anti-Set7/9 polyclonal (Millipore), anti-E2F-1, anti-Cdc6, anti-DHFR, anti-Cdc25A, anti-Cdc2, anti-GAPDH (glyceradehyde 3 phosphate dehydrogenase) monoclonal (Santa Cruz Biotechnology), and anti-actin monoclonal (Sigma).
In vitro protein methylation assay Methylation assays were carried out for 1 h at 30 1C in 30 ml HMT buffer (50 mM Tris (pH 8.5), 100 mM NaCl, 1 mM EDTA, 1 mM DTT), using 1 mg of GST-Set7/9 enzyme, 1 mg of the indicated substrate or calf thymus histones (Roche) and 1 mM S-adenosyl-[ 3 H-methyl]-methionine (Amersham, Little Chalfont, UK). Reactions were spotted onto P81 membrane circles (Whatman, Maidstone, UK) or the total reaction was mixed with 2 Â SDS loading buffer and applied to SDS-PAGE gels for electrophoresis. P81 membranes were subsequently washed thrice in 50 mM NaHCO 3 (pH 9.2) and dried in acetone. Dry membranes were added to scintillation cocktail (Beckman Coulter, Palatine, IL, USA) and the incorporation of radiolabel was measured on a scintillation counter. The SDS-PAGE gels were fixed and stained with Coomassie Blue before being incubated in Amplify (Pharmacia, Milton Keynes, UK), dried and exposed to film.
Flat cell assay SAOS2 cells were grown on 6-cm plates to 70% confluency and transfected with 2 mg pSG5L-HA-Rb and 0.5 mg pcDNA3. Stable transfectants were selected and grown in DMEM containing 10% FCS and 1 mg/ml G418 for 2 weeks. Cells were stained for SA-b-gal activity (Dimri et al., 1995) ; flat cells were identified by strong blue staining and manually counted.
Immunostaining U2OS and SAOS2 cells were stained according to previously published procedures (Markham et al., 2006) .
Luciferase assays
For reporter assays, U2OS or SAOS2 cells were transfected with 0.2 mg of luciferase reporter plasmid, 0.2 mg of pCMVb-galactosidase (b-gal) plasmid as an internal control and the indicated expression plasmids as previously described (Chan et al., 2001) .
Flow cytometry SAOS2 cells were transfected with 2 mg of the indicated plasmids together with 0.5 mg CD20 to identify the transfected population. At 36 h after transfection, cells were collected using cell dissociation buffer (Sigma). The cells were then washed in PBS and fixed overnight in 50% ethanol/PBS at 4 1C. Fixed cells were washed in PBS and incubated for 30 min with 25 U/ml RNase A (Sigma) and 50 mg/ml propidium iodide (Sigma) in PBS. The analysis of cell cycle profiles was performed as previously described. Set7/9 depletion Cells were transfected with 25 nM Set7/9 (5-AGAUAACAUU CGUCAUGGA-3), control GAPDH or non-targeting control #2 (Dharmacon, Chicago, IL, USA) siRNA using oligofectamine transfection reagent (Invitrogen), as per the manufacturer's instructions.
Chromatin immunoprecipitation
The C2C12 cells were maintained in DMEM containing 10% FCS, however, for differentiation they were cultured in the presence of medium containing 1% horse serum. The U2OS cells were grown under serum deprivation conditions (0.1% FCS) for 48 h. Cells were cross-linked with DMA followed by formaldehyde. chromatin immunoprecipitation samples were prepared as described previously (Zalmas et al., 2008) . Immunoprecipitations were performed using 2 mg anti-Rb (G3-245; BD Biosciences, Franklin Lakes, NJ, USA), antiHP1a (Millipore) or mouse non-specific IgG (Santa Cruz Biotechnology). Immunoprecipitate and inputs were reverse cross-linked, DNA purified and analysed by real-time quantitative PCR.
Quantitative PCR Real-time PCR for the chromatin immunoprecipitation was carried out according to the manufacturer's instructions using Brilliant II SYBR Green QPCR Master Mix. The primers used were as follows: DHFR forward: 5-GCCTAAGCT GCGCAA GTGGT-3; DHFR reverse: 5-GTCTCCGTTCTTGCCAAT CC-3; TS forward primer 5-CTG CCAGCTGTACCAGAC AT-3; TS reverse primer 5-ATGTGCATCTCCCAAAGTG T-3 as described (Kinkade et al., 2008; Vandromme et al., 2008) .
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